8-K: Phio Pharmaceuticals' PH-762 Shows Encouraging Safety Profile, Advances to Third Dose Cohort

Phio Pharmaceuticals' lead compound, PH-762, demonstrated a positive safety profile in its Phase 1b clinical trial, leading to a recommendation to escalate to the next dose concentration.

Summary

• Phio Pharmaceuticals announced that the Safety Monitoring Committee (SMC) has recommended dose escalation in its Phase 1b clinical trial for PH-762.
• The trial is evaluating the safety and tolerability of PH-762 in treating various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
• The second cohort of the trial enrolled four patients with cutaneous squamous cell carcinoma.
• The first two patients who completed treatment showed a complete response (100% tumor clearance) and a partial response (90% clearance) at Day 36.
• The intratumoral injections of PH-762 have been well tolerated, with no dose-limiting toxicities or serious adverse events reported.
• Pathology data for the remaining two patients is forthcoming.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the encouraging safety and efficacy data from the clinical trial, as well as the recommendation to escalate the dose. The absence of serious adverse events further supports this positive outlook.

Positives

• The Safety Monitoring Committee's recommendation to escalate the dose indicates confidence in the safety profile of PH-762.
• The complete and partial responses observed in the first two patients of the second cohort are promising signs of efficacy.
• The absence of dose-limiting toxicities and serious adverse events suggests a favorable safety profile for PH-762.
• The company's INTASYL technology is designed to enhance the ability of immune cells to kill tumor cells.

Risks

• The company's forward-looking statements are subject to uncertainties, risks, and changes in circumstances.
• Actual results may differ materially from those indicated in the forward-looking statements due to various factors, including the development of product candidates, regulatory approvals, and market conditions.
• The company's ability to obtain future financing is a risk factor.

Future Outlook

The company plans to continue enrollment in the clinical study and further develop PH-762 for the treatment of cutaneous carcinomas.

Management Comments

• Safety and efficacy data from our clinical trial continues to be encouraging as we develop PH-762 for the treatment of cutaneous carcinomas said Mary Spellman MD, Phios acting Chief Medical Officer.
• We look forward to continued enrollment in the clinical study.

Industry Context

This announcement is relevant to the immuno-oncology field, where companies are developing novel therapies to enhance the body's immune response to cancer. The use of siRNA technology to silence specific genes like PD-1 is a growing area of interest.

Comparison to Industry Standards

• The reported 100% and 90% tumor clearance rates in the first two patients are promising compared to standard treatments for cutaneous squamous cell carcinoma, which often involve surgery, radiation, or chemotherapy.
• Companies like Regeneron and Merck have also been developing immuno-oncology drugs, but Phio's approach using siRNA gene silencing is a unique approach.
• The absence of dose-limiting toxicities is a positive sign, as many cancer therapies are associated with significant side effects.

Stakeholder Impact

• Shareholders may view this announcement positively due to the encouraging clinical trial results.
• Patients with skin cancers may benefit from the development of PH-762 as a potential non-surgical treatment.
• Employees of Phio Pharmaceuticals may be motivated by the progress of the clinical trial.

Next Steps

• The company will continue enrollment in the clinical study.
• The company will escalate to the next dose concentration in the Phase 1b trial.
• Pathology data for the remaining two patients in the second cohort is forthcoming.

Key Dates

Keywords

PH-762, INTASYL, siRNA, gene silencing, immuno-oncology, cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma, clinical trial, Safety Monitoring Committee, dose escalation, tumor clearance, PD-1